Gilead Sciences must pay $1.8 million in attorney fees and costs after denying shareholders access to records Biopharmaceutical company Gilead Sciences was ordered to pay attorneys' fees and expenses to shareholders who were denied information they say may have shed light on alleged anticompetitive practices related to the company's breakthrough HIV antiviral drug. The Gilead Sciences headquarters in Foster City, Calif., in April 2020. (AP Photo/Ben Margot, File) (CN) — A Delaware court on Thursday ordered Gilead Sciences Inc. to pay nearly $1.8 million in attorneys' fees and legal expenses to shareholders who sued the biopharmaceutical company for records related to its development and marketing of HIV drugs.